High frequency of potential phosphodiesterase type 5 inhibitor drug interactions in males with HIV infection and erectile dysfunction

被引：1

作者：

Cota, Jason M. ^{[1
]}

Benavides, Taylor M. ^{[1
]}

Fields, John D. ^{[1
]}

Jansen, Nathan ^{[2
]}

Ganesan, Anuradha ^{[3
,4
,5
]}

Colombo, Rhonda E. ^{[3
,5
,6
]}

Blaylock, Jason M. ^{[4
]}

Maves, Ryan C. ^{[5
,7
]}

Agan, Brian K. ^{[3
,5
]}

Okulicz, Jason F. ^{[2
]}

机构：

[1] Univ Incarnate Word, San Antonio, TX USA

[2] San Antonio Mil Med Ctr, Ft Sam Houston, TX USA

[3] Henry M Jackson Fdn Adv Mil Med, Bethesda, MD USA

[4] Walter Reed Natl Mil Med Ctr, Bethesda, MD USA

[5] Uniformed Serv Univ Hlth Sci, Infect Dis Clin Res Program, Bethesda, MD 20814 USA

[6] Madigan Army Med Ctr, Joint Base Lewis Mcchord, WA USA

[7] Naval Med Ctr, San Diego, CA USA

来源：

PLOS ONE | 2021年 / 16卷 / 05期

基金：

美国国家卫生研究院;

关键词：

SEXUAL DYSFUNCTION; SILDENAFIL; ASSOCIATION; PREVALENCE; RISK; MEN;

D O I：

10.1371/journal.pone.0250607

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Objectives We sought to determine the prevalence of phosphodiesterase type 5 inhibitor (PDE-5) mediated drug-drug interactions (DDIs) in males with HIV infection receiving antiretroviral therapy (ART) and identify factors associated with PDE-5-mediated DDIs. Methods Male US Military HIV Natural History Study participants diagnosed with erectile dysfunction (ED) and having a PDE-5 inhibitor and potentially-interacting ART co-dispensed within 30 days were included. DDIs were defined according to criteria found in published guidelines and drug information resources. The primary outcome of interest was overall PDE-5 inhibitor-mediated DDI prevalence and episode duration. A secondary logistic regression analysis was performed on those with and without DDIs to identify factors associated with initial DDI episode. Results A total of 235 male participants with ED met inclusion criteria. The majority were White (50.6%) or African American (40.4%). Median age at medication co-dispensing (45 years), duration of HIV infection (14 years), and duration of ED (1 year) did not differ between the two groups (p>0.05 for all). PDE-5 inhibitors included sildenafil (n = 124), vardenafil (n = 99), and tadalafil (n = 14). ART regimens included RTV-boosted protease inhibitors (PIs) atazanavir (n = 83) or darunavir (n = 34), and COBI-boosted elvitegravir (n = 43). Potential DDIs occurred in 181 (77.0%) participants, of whom 122 (67.4%) had multiple DDI episodes. The median DDI duration was 8 (IQR 1-12) months. In multivariate analyses, non-statistically significant higher odds of DDIs were observed with RTV-boosted PIs or PI-based ART (OR 2.13, 95% CI 0.85-5.37) and in those with a diagnosis of major depressive disorder (OR 1.74, 95% CI 0.83-3.64). Conclusions PDE-5-mediated DDIs were observed in the majority of males with HIV infection on RTV- or COBI-boosted ART in our cohort. This study highlights the importance of assessing for DDIs among individuals on ART, especially those on boosted regimens.

引用

页数：11

共 29 条

[21] Predictors of Clinically Significant Drug-Drug Interactions Among Patients Treated with Nonnucleoside Reverse Transcriptase Inhibitor-, Protease Inhibitor-, and Raltegravir-Based Antiretroviral Regimens [J].